Table 1 Patient demographics and clinical characteristics of patients divided by AI-based TSP and KELIM.

From: STAR (stroma-tumor AI risk) assessment: association of AI-derived tumor-stroma proportion with patient survival provides added prognostic value beyond KELIM in epithelial ovarian cancer

Characteristics

Patients, No. (%)

 

All (n = 89)

TSP < 50% (n = 40)

TSP ≥ 50% (n = 49)

P valuea

KELIM < 1 (n = 54)

KELIM ≥ 1 (n = 35)

P valuea

Age at diagnosis (yr), mean (SD)

61.8 (9.5)

62.0 (8.6)

61.6 (10.3)

0.877

61.9 (10.0)

61.5 (8.9)

0.854

KELIM, median (range)

0.9 (0.3, 2.3)

0.9 (0.4, 2.3)

0.8 (0.3, 1.9)

-

0.7 (0.3, 1.0)

1.3 (1.0, 2.3)

-

Histology, n (%)

 High Grade Serous

72 (80.9%)

29 (72.5%)

43 (87.8%)

0.258

41 (75.9%)

31 (88.6%)

0.055

 Clear Cell

7 (7.9%)

4 (10.0%)

3 (6.1%)

6 (11.1%)

1 (2.9%)

 Endometrioid

3 (3.4%)

2 (5.0%)

1 (2.0%)

0 (0.0%)

3 (8.6%)

 Mucinous

2 (2.2%)

2 (5.0%)

0 (0.0%)

2 (3.7%)

0 (0.0%)

 Carcinosarcoma

2 (2.2%)

2 (5.0%)

0 (0.0%)

2 (3.7%)

0 (0.0%)

 Mixed

2 (2.2%)

1 (2.5%)

1 (2.0%)

2 (3.7%)

0 (0.0%)

 Undifferentiated

1 (1.1%)

0 (0.0%)

1 (2.0%)

1 (1.9%)

0 (0.0%)

FIGO Stage, n (%)

 Stage IC

7 (7.9%)

5 (12.5%)

2 (4.1%)

0.177

4 (7.4%)

3 (8.6%)

0.740

 Stage IIA

4 (4.5%)

3 (7.5%)

1 (2.0%)

3 (5.6%)

1 (2.9%)

 Stage IIB

5 (5.6%)

3 (7.5%)

2 (4.1%)

4 (7.4%)

1 (2.9%)

 Stage IIIA

3 (3.4%)

2 (5.0%)

1 (2.0%)

3 (5.6%)

0 (0.0%)

 Stage IIIB

15 (16.9%)

8 (20.0%)

7 (14.3%)

10 (18.5%)

5 (14.3%)

 Stage IIIC

32 (36.0%)

9 (22.5%)

23 (46.9%)

18 (33.3%)

14 (40.0%)

 Stage IV

23 (25.8%)

10 (25.0%)

13 (26.5%)

12 (22.2%)

11 (31.4%)

Timing of Therapy, n (%)

 Adjuvant therapy

53 (59.6%)

26 (65.0%)

27 (55.1%)

0.344

33 (61.1%)

20 (57.1%)

0.709

 NACT

36 (40.4%)

14 (35.0%)

22 (44.9%)

21 (38.9%)

15 (42.9%)

Platinum Status, n (%)

 Sensitive

67 (75.3%)

32 (80.0%)

35 (71.4%)

0.351

37 (68.5%)

30 (85.7%)

0.066

 Resistant

22 (24.7%)

8 (20.0%)

14 (28.6%)

17 (31.5%)

5 (14.3%)

Optimal Resection, n (%)

 Unknown

2

0

2

0.065

2

0

 

 Yes

79 (90.8)

39 (97.5%)

40 (85.1%)

44 (84.6%)

35 (100.0%)

0.019

 No

8 (9.2%)

1 (2.5%)

7 (14.9%)

8 (15.4%)

0 (0.0%)

Germline BRCA1/2 and HR status, n (%)

 BRCA1-mt

9 (10.8%)

5 (13.2%)

4 (8.9%)

0.755

3 (6.1%)

6 (17.6%)

0.572

 BRCA2-mt

9 (10.8%)

3 (7.9%)

6 (13.3%)

6 (12.2%)

3 (8.8%)

 BRCA1/2-wt, HRD

7 (8.4%)

2 (5.3%)

5 (11.1%)

5 (10.2%)

2 (5.9%)

 BRCA1/2-wt, HRP

20 (24.1%)

10 (26.3%)

10 (22.2%)

12 (24.5%)

8 (23.5%)

 BRCA1/2-wt, HR unknown

38 (45.8%)

18 (47.4%)

20 (44.4%)

23 (46.9%)

15 (44.1%)

 Unknown

6

2

4

5

1

  1. TSP tumor stroma proportion, KELIM k elimination constant of CA-125, NACT neoadjuvant chemotherapy, BRCA breast cancer gene, HR homologous recombination, mt mutant, wt wild type, HRD homologous recombination deficient; homologous recombination proficient.
  2. aComparison of categorical variables were conducted using Chi-square or Fisher’s exact test, and the comparison of age and KELIM score between groups was conducted using Student’s ttest or Wilcoxon rank-sum test, respectively.
Back to article page